159 related articles for article (PubMed ID: 37987969)
1. The clinical signification and application value of [
Feng YY; Shi YR; Xia Z; Xu L; Li WB; Pang H; Wang ZJ
Endocrine; 2024 May; 84(2):598-606. PubMed ID: 37987969
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3.
de Vries LH; Lodewijk L; Braat AJAT; Krijger GC; Valk GD; Lam MGEH; Borel Rinkes IHM; Vriens MR; de Keizer B
EJNMMI Res; 2020 Mar; 10(1):18. PubMed ID: 32144510
[TBL] [Abstract][Full Text] [Related]
4. The Utility of Prostate-Specific Membrane Antigen-11 PET in Detection and Management of Central Nervous System Neoplasms.
Dawod M; Rush E; Nagib PB; Aduwo J; Bodempudi P; Appiah-Kubi E
Clin Nucl Med; 2024 Jul; 49(7):e340-e345. PubMed ID: 38598534
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract][Full Text] [Related]
6. Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer-A New Diagnostic and Therapeutic Target?
Wächter S; Di Fazio P; Maurer E; Manoharan J; Keber C; Pfestroff A; Librizzi D; Bartsch DK; Luster M; Eilsberger F
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830843
[TBL] [Abstract][Full Text] [Related]
7. Gallium-68 prostate-specific membrane antigen ([
Lawhn-Heath C; Yom SS; Liu C; Villanueva-Meyer JE; Aslam M; Smith R; Narwal M; Juarez R; Behr SC; Pampaloni MH; Chan JW; Glastonbury CM; Hope TA; Flavell RR
EJNMMI Res; 2020 Oct; 10(1):128. PubMed ID: 33090273
[TBL] [Abstract][Full Text] [Related]
8. Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
Lütje S; Gomez B; Cohnen J; Umutlu L; Gotthardt M; Poeppel TD; Bockisch A; Rosenbaum-Krumme S
Clin Nucl Med; 2017 Jan; 42(1):20-25. PubMed ID: 27846003
[TBL] [Abstract][Full Text] [Related]
9. The value of Gallium-68 prostate-specific membrane antigen ([
Shi Y; Feng Y; Xu L; Li W; Guan L; Zuo R; Liu S; Pang H; Wang Z
Br J Radiol; 2023 Jul; ():20230291. PubMed ID: 37393530
[TBL] [Abstract][Full Text] [Related]
10. The frequency of thyroid incidental findings and risk of malignancy detected by
Gossili F; Petersen LJ; Zacho HD
Hell J Nucl Med; 2020; 23(3):240-245. PubMed ID: 33306753
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of peptide-based imaging agents [
Zhang-Yin J; Provost C; Cancel-Tassin G; Rusu T; Penent M; Radulescu C; Comperat E; Cussenot O; Montravers F; Renard-Penna R; Talbot JN; Prignon A
Nucl Med Biol; 2020; 84-85():88-95. PubMed ID: 32251995
[TBL] [Abstract][Full Text] [Related]
12. Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Verma P; Malhotra G; Agrawal R; Sonavane S; Meshram V; Asopa RV
Clin Nucl Med; 2018 Aug; 43(8):e265-e268. PubMed ID: 29894335
[TBL] [Abstract][Full Text] [Related]
13. The Added Value of
Chen R; Wang Y; Zhu Y; Shi Y; Xu L; Huang G; Liu J
J Nucl Med; 2022 Jan; 63(1):69-75. PubMed ID: 34980667
[No Abstract] [Full Text] [Related]
14. Head-to-Head Comparison of
Pitalua-Cortes Q; García-Perez FO; Vargas-Ahumada J; Gonzalez-Rueda S; Gomez-Argumosa E; Ignacio-Alvarez E; Soldevilla-Gallardo I; Torres-Agredo L
Front Endocrinol (Lausanne); 2021; 12():794759. PubMed ID: 35002972
[TBL] [Abstract][Full Text] [Related]
15. Head-to-head comparisons of
Lin BH; Chen SH; Chen SM; Qiu QR; Gao RC; Wei Y; Zheng QS; Miao WB; Xu N
Int Urol Nephrol; 2023 Nov; 55(11):2753-2764. PubMed ID: 37477778
[TBL] [Abstract][Full Text] [Related]
16. Prospective intra-individual blinded comparison of [
Pattison DA; Debowski M; Gulhane B; Arnfield EG; Pelecanos AM; Garcia PL; Latter MJ; Lin CY; Roberts MJ; Ramsay SC; Thomas PA
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):763-776. PubMed ID: 34383089
[TBL] [Abstract][Full Text] [Related]
17.
Gündoğan C; Ergül N; Çakır MS; Kılıçkesmez Ö; Gürsu RU; Aksoy T; Çermik TF
Mol Imaging Radionucl Ther; 2021 Jun; 30(2):79-85. PubMed ID: 34082503
[TBL] [Abstract][Full Text] [Related]
18. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
19. The prostate-specific membrane antigen (PSMA)-targeted radiotracer
Santhanam P; Russell J; Rooper LM; Ladenson PW; Pomper MG; Rowe SP
Med Oncol; 2020 Oct; 37(11):98. PubMed ID: 33034761
[TBL] [Abstract][Full Text] [Related]
20. The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.
Arslan E; Ergül N; Beyhan E; Erol Fenercioglu Ö; Sahin R; Cin M; Battal Havare S; Can Trabulus FD; Mermut Ö; Akbas S; Fikret Çermik T
Nucl Med Commun; 2023 Apr; 44(4):284-290. PubMed ID: 36756767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
